Prima BioMed is a biotechnology that is active throughout the world. A leader in personalized bio-therapeutic cancer products, the company is focused on leveraging its current technology and expertise in developing innovative treatment options for patients as well as maximizing shareholder value. CVac, the company’s lead product, is an autologous dendritic cell product presently in clinical trials for ovarian cancer patients in remission. For more information, visit the company’s Web site at www.primabiomed.com.au.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: